SPARETECH aims to cut manufacturers’ spare parts inventory by 60% within three years with AI that ensures parts are available when they are needed

MUNICH, Nov. 10, 2026 — SPARETECH, a provider of enterprise AI for spare parts management, today announced it has raised $20 million in Series B funding to help manufacturers cut their spare parts inventory without risking downtime. Blume Equity and Insight Partners co-led the round, with participation from Headline.

Geographic expansion and growth trajectory

SPARETECH has established itself in the United States and grown its revenue fivefold since the start of 2024. Over the same period, the company grew its spare parts catalog to more than 40 million verified parts and expanded its network to 15,000 manufacturer and supplier partners. The global rollout of Nestlé, a SPARETECH customer, put 320 plants across 70 countries live in less than a year, further affirming SPARETECH’s global enterprise capabilities and speed.

“Every customer we work with wants the same thing: the production line running with less inventory on the shelf. That is the problem we are going to solve with Maintenance teams, and our goal is to cut spare parts inventory by 60% in the next three years, while securing the same uptime.”
Martin Weber, CEO and Co-Founder, SPARETECH

Why spare parts stay on the shelf

Spare parts management has long been one of manufacturing’s most persistent inefficiencies. A single stockout can halt production and idle an entire line, making plants default to holding extensive spare parts inventories as a safeguard. The result is a substantial amount of capital sitting on the shelf. SPARETECH’s 2026 benchmark report puts the average value of spare parts inventory at $169 million per company.

Source: Unlocking cost savings in spare parts management: The 2026 benchmark report on MRO spend, productivity, and working capital, SPARETECH, 2026.

From visibility to availability

Since its founding, SPARETECH has helped customers gain visibility into the parts they hold and standardize their spare parts data, which is the foundation of effective spare parts management. Meaningfully reducing inventory levels, however, requires more than good data. It requires physical action.

SPARETECH is moving the market beyond insights and recommendations toward measurable outcomes: lower inventory with the same uptime. To reach the 60% goal, every maintenance professional needs confidence that the right part will be available when needed, even if it sits on another company’s shelf. SPARETECH’s AI will secure that availability.

“Every part sitting idle is cash that could be working somewhere else. We are building AI that makes sure the right part is available when a plant needs it and put those idle parts back into circulation, so the money tied up on the shelf can go back to growing the business.”
Dr. Lukas Biedermann, COO and Co-Founder, SPARETECH

Why now

Industrial automation keeps expanding, and a single new production line can add thousands of spare parts that someone has to stock. The problem grows with every machine that is installed. With the cost of capital rising, manufacturers can no longer afford to keep that much money sitting on the shelf. At the same time, AI can now secure availability at a scale no team could manage by hand.

“Often building resilience in supply chain ends up in building more inventories for spare parts. A much more suitable way would be a system, which secures better resilience with up to 60% less inventories sitting on the shelves. SPARETECH is exactly doing this. A fascinating opportunity especially for the manufacturing industry.”
Joe Kaeser, Chairman of the Supervisory Board of Siemens Energy and Daimler Truck 

“SPARETECH is exactly the kind of business we back. Idle spare parts are a large, overlooked pool of wasted resources, and putting them back to work gives manufacturers a measurable return and the planet less waste. We are delighted to partner with Martin, Lukas, and the team as they scale.”
Michelle Capiod, Co-Founding Partner, Blume Equity

Investing in innovation and expansion

SPARETECH will use the funding to continue building the AI that secures spare part availability for industrial companies and put their surplus parts back into circulation, expand its presence in North America and new regions, and deepen its work with existing customers.

“The next stage of SPARETECH’s growth runs through North America. American manufacturers operate large plant networks with a lot of capital tied up in spare parts, and they need a partner built for that scale. Insight has spent decades helping software companies grow in the United States, and we are excited to support Martin, Lukas, and the team as they scale.”
Brad Fiedler, Managing Director, Insight Partners

“The digital world is moving into the physical one, and Germany has the industrial substance to lead that shift. SPARETECH is building industrial AI for spare parts management, and it already gives maintenance and procurement teams confidence in uncertain times. This is where industrial AI starts to pay off for global manufacturers.”
Christian Miele, General Partner, Headline

Learn more at sparetech.io.

About SPARETECH

SPARETECH’s enterprise AI software empowers global manufacturers to reduce their spare parts spend and inventory. Built on verified original manufacturer data, the platform standardizes material master data, right-sizes inventory across plants, and enables sourcing and surplus resale across the network. Maintenance and procurement teams know what they have, get what they need, and sell what they don’t.

Trusted by manufacturers like Nestlé, Porsche, VW, Bosch, and Sanofi, the company is moving toward its vision of a zero-waste industrial sharing economy.

About Blume Equity

Blume Equity is a European growth equity firm based in London and Amsterdam, backing technology companies that build cleaner energy systems, smarter industry and more climate-resilient economies. Its team works closely with founders to help businesses scale and create long-term value.

For more information, visit blumeequity.com.

About Insight Partners

Insight Partners is a global AI and software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2026, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 900 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has a global presence with leadership in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow on X @insightpartners.

About Headline

Headline is a venture capital firm that partners with exceptional technology teams with global ambitions. The firm manages more than $5 billion in assets and invests through regionally focused early-stage funds across the US, Europe, Asia, and Latin America, as well as Headline Growth, which invests worldwide from Series B to the public market. Headline is headquartered in San Francisco and has eight global offices. Learn more at headline.com.

Media contact:
Charles Mackenzie
VP Marketing, SPARETECH
[email protected] 

WALTHAM, Mass., Nov. 10, 2026 — EnVision Endoscopy, Inc., a medical technology company developing innovative solutions for gastrointestinal (GI) endoscopic surgery, today announced the successful closing of an oversubscribed $11.5 million Series A financing and the completion of its first 50 patient procedures using the SimpleStitch™ Suturing System.

Together, these milestones mark a significant step in the company’s transition from technology development to clinical adoption and commercial expansion, supporting its mission to make endoscopic suturing more accessible to physicians performing minimally invasive gastrointestinal procedures.

Designed for use with standard flexible endoscopes, the SimpleStitch™ Suturing System is intended to help physicians with an intuitive approach and easy-to-use technology to perform endoscopic suturing. The technology is designed to address longstanding challenges associated with tissue closure following advanced gastrointestinal endoscopic procedures, potentially expanding access to suturing beyond specialized expert centers.

EnVision received FDA clearance for the SimpleStitch™ Suturing System in 2025 and initiated a limited U.S. market release in 2026. The completion of the first 50 patient procedures represents an important milestone in building clinical experience, strengthening physician partnerships, and advancing the company’s commercial strategy.

“Technologies to simplify endoscopic resection are coming, and closure should be even simpler. SimpleStitch™ bridges the gap between conventional clips and advanced endoscopic suturing, making strong, confident tissue closure more accessible. I’m excited that 50 procedures have now been safely completed at pilot sites in 2026. This is an important step toward bringing better closure options to physicians and their patients,” said Dr. Andrew Storm of Atrium Health Wake Forest Baptist, who performed the first-in-human procedure with SimpleStitch™.

“We founded EnVision to address persistent challenges in endoscopic surgery. Reaching our first 50 patient procedures validates the work of our team and physician collaborators in bringing SimpleStitch™ into clinical practice. Combined with our Series A financing, this milestone positions us to build on that momentum and bring our technology to more physicians and patients,” said Azadeh Khanicheh, Ph.D., Co-Founder and Chief Executive Officer of EnVision Endoscopy.

Series A Financing to Support Commercial Expansion
The oversubscribed $11.5 million Series A financing was led by Puma Venture Capital, with participation from UTEC – University of Tokyo Edge Capital, existing investor Olympus Corporation of the Americas, and MassVentures.

“Puma backs minimally invasive technologies that can improve both labor productivity and how well patients do. SimpleStitch™ takes endoscopic suturing out of a handful of expert centers and puts it on the scope a physician already owns. More endoscopists can close with confidence, more patients get a less invasive option, and that’s why we led this round,” said Amit Hazan, Co-Founder and Managing Partner of Puma Venture Capital.

The financing will support EnVision Endoscopy’s next phase of growth, including expanded commercial availability, physician training, clinical evidence generation, manufacturing scale-up, and further product development.

The strong investor participation reflects confidence in EnVision Endoscopy’s technology, its approach to addressing unmet needs in gastrointestinal endoscopic surgery, and the growing opportunity to advance minimally invasive endoscopic interventions.

Addressing a Growing Need for Endoscopic Closure
Endoscopy is steadily replacing surgery for a growing range of gastrointestinal conditions. More than 20 million gastrointestinal endoscopic procedures are performed in the U.S. each year, and advanced resection techniques such as endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and peroral endoscopic myotomy (POEM) are being adopted rapidly in the U.S. and Europe. Each of these procedures can leave defects that need secure closure.

The endoscopic closure device market is projected to grow 7–8% annually through the end of the decade. Yet endoscopic suturing remains concentrated in a small number of expert centers, because existing systems require extensive training and dedicated equipment. SimpleStitch™ is designed to close this gap by bringing suturing to the broader community of endoscopists using the endoscopes they already have.

About EnVision Endoscopy, Inc.
EnVision Endoscopy, Inc. is a Waltham, Massachusetts-based medical technology company developing innovative devices for gastrointestinal endoscopic surgery. Co-founded by Azadeh Khanicheh, Ph.D., and Christopher C. Thompson, MD, MSc, the company is focused on addressing unmet clinical needs through technologies that support less invasive endoscopic procedures.

Its SimpleStitch™ Suturing System is designed to facilitate endoscopic suturing and tissue approximation using standard flexible endoscopes. EnVision’s mission is to advance endoscopic surgery through practical, innovative technologies that serve physicians and patients.

For more information, visit: www.envisionendoscopy.com

SOURCE ENVISION ENDOSCOPY INC.

Investec-led financing recapitalizes operating assets and funds new construction projects

BOSTON, Nov. 10, 2026 — Calibrant Energy, a leading provider of on-site energy solutions, today announced the close of a $145 million debt facility led by Investec for solar and battery storage projects across multiple U.S. power markets. The portfolio includes a 120 megawatt-hour (MWh) battery energy storage system (BESS) serving a hyperscale data center customer in PJM. Citi, Liberty Bank, and Siemens Financial Services also participated in the facility.

Data center operators are looking for ways to get online faster as PJM and federal regulators work through how large power users connect to the grid. Calibrant’s engineered BESS solutions give energy-intensive facilities greater control over how and when they draw power. This flexibility supports faster interconnection timelines and reduces the need for costly grid infrastructure upgrades that would otherwise be passed on to other ratepayers.

“Data center operators are choosing on-site energy storage because it is a fast, reliable, and effective way to get online and operate as responsible grid citizens,” said Phil Martin, CEO of Calibrant Energy. “With this financial close and site mobilization for a hyperscale data center, Calibrant continues to demonstrate that large-load flexibility is not just possible but a commercial reality today.”

Calibrant’s turnkey, zero-capex solutions unlock the path to reliable power that the world’s largest power users need to grow their businesses.

“Investec is proud to support Calibrant and Macquarie on this transaction,” said Fred Petit, Co-Head of Energy & Infrastructure North America at Investec. “We value the opportunity to partner with experienced investors and operators, and to provide financing that advances the energy transition and the critical infrastructure needed to meet growing power demand across the U.S.”

Calibrant Energy now has more than 5.9 gigawatt-hours (GWh) of battery storage capacity in operation, in construction, or under exclusive development agreements, including additional sites with the same hyperscale customer. This growth reflects rising demand from large power users for on-site energy solutions that accelerate speed to power while easing strain on the grid. It also reflects customers’ preference for a trusted, experienced partner that can develop, own, and operate these solutions and deliver the power outcomes their business plans depend on.

About Calibrant Energy: Calibrant Energy is a leading provider of on-site energy solutions for large power users. Calibrant’s turnkey, zero-capex solutions unlock the paths to power that the world’s largest power users need to grow their businesses, while enabling a more reliable, affordable, and sustainable power grid. As the trusted on-site energy partner to many of the world’s largest enterprises, Calibrant has more than 2.2 GW / 5.9 GWh of projects in operation, construction, or under exclusive development agreements. Calibrant is backed by Macquarie Asset Management. Learn more at www.calibrantenergy.com

About Investec: Investec Bank plc (‘IBP’) is the banking subsidiary of Investec plc. Investec plc is a FTSE 100 listed company which holds the majority of Investec Group’s non-Southern African businesses under a dual listed company structure. IBP partners with private, institutional and corporate clients, offering banking and investment services in the UK, Europe and certain other countries.

IBP also offers wealth management services through its strategic combination with Rathbones Group.  IBP has operated in the UK since 1992. As part of the Investec Group, IBP is a purpose-driven organisation, dedicated to its core purpose of creating enduring worth. This means we will always strive to create long-term value for all stakeholders and contribute meaningfully to people, communities and the planet. Further information can be found at www.investec.com.

SOURCE Calibrant Energy

A leader in self-storage and parcel retail, Supply Side serves more than 30,000 businesses across the U.S. and Canada

DALLAS, Nov. 10, 2026 — Broadwing Capital, the Dallas-based private equity firm specializing in the lower middle-market manufacturing and services sectors, today announced its acquisition of Supply Side, the first investment in its new specialty distribution platform. Based in Cleveland, Supply Side distributes packaging materials and hardware, including boxes, tape, bubble wrap, and locks to some of the largest self-storage and parcel shipping operators across the U.S. and Canada.

Supply Side anchors Broadwing’s new platform with a leading position in both self-storage and parcel retail, serving more than 30,000 locations. By designing and stocking the full retail supply display, the company helps its customers operate more securely and efficiently while giving consumers a one-stop shop for moving, storing, and shipping.

“Supply Side brings together the qualities we look for in a platform investment: a strong competitive position in essential, resilient markets, a proven management team, and clear opportunities to grow,” said Eliot Kerlin, Jr., Co-Founder and Managing Partner at Broadwing Capital. “Ansir Junaid has been an outstanding leader for Supply Side, growing the business significantly and building a strong, talented team around him. We’re thrilled to make Supply Side the foundation for our new specialty distribution platform and partner with Junaid and his team on the company’s next phase of growth.”

“We met with a number of private equity firms, and Broadwing stood apart for how much they valued our people and our customers,” said Ansir Junaid, Chief Executive Officer of Supply Side. “Throughout the process, they listened carefully and followed through on every commitment they made. With Broadwing’s strategic depth and discipline behind us, our team is ready to grow Supply Side into new markets and product lines.”

Junaid acquired Supply Side in 2008 after serving the company as a sourcing and logistics partner. Under his leadership, Supply Side significantly grew its self-storage business and built the infrastructure to serve national customers across the U.S. and Canada. He will continue to lead the company as Chief Executive Officer alongside its existing management team and remains an investor in the business.

About Broadwing Capital
Broadwing is a Dallas-based private equity firm specializing in lower middle market manufacturing and services investments. The firm thoughtfully scales niche platforms into market leaders through hands-on operational support that enhances companies, cultures, and communities. Broadwing is known for its founder-friendly approach, experienced team of resource partners, and a values-driven commitment to long-term growth. Since its founding in 2022 by two long-time private equity investors, Broadwing has raised over $730 million of committed capital and closed 26 acquisitions. To learn more, visit our website and follow us on LinkedIn.

About Supply Side
Founded in 1960, Supply Side is a Cleveland-based distributor of packaging materials and hardware for the self-storage and parcel retail industries. The company serves more than 30,000 businesses across the U.S. and Canada, from single storage facilities to regional retail chains and nationwide brands, helping them operate more securely, efficiently, and profitably. Backed by strong supplier partnerships, deep product knowledge, and a commitment to innovation, Supply Side designs and stocks complete retail supply displays that help customers protect their assets, streamline operations, and improve the customer experience. To learn more, visit Supplyside.com.

Media Contact
[email protected] 

SOURCE Broadwing Capital

MyoWorks’ deep musculoskeletal expertise enables the company to tool its physical AI applications to drive measurable productivity and economic gains for care providers

WINDSOR, Wis., Nov. 10, 2026 — MyoWorks, a Wisconsin-based healthcare technology startup, announced today that it has secured an investment from Mastercraft Ventures to develop smart treatment devices for chiropractors, physical therapists, and other musculoskeletal care providers.

MyoWorks’ smart handheld instruments combine multiple treatment methods with software that captures clinical data and automates documentation. The company aims to use this data to track patient progress, inform clinical decisions, and ultimately improve patient outcomes.

“Chiropractic has always been part art and part science, but existing tools capture very little of that knowledge,” said Dr. Jeremy Quick, Founder of MyoWorks. “Mastercraft Ventures’ support enables us to scale our software and physical AI systems, transforming insights into the delivery of treatments and actionable intelligence in the form of a more measurable patient response. This drives greater care efficiencies and will help advance musculoskeletal care for patients worldwide.”

Dr. Quick developed the concept after more than a decade as a practicing chiropractor. By combining treatments traditionally performed separately, he was able to deliver more care during each appointment and increase practice revenue by 20%. He founded MyoWorks to help other practitioners achieve similar results.

MyoWorks is initially targeting the instrument-assisted soft tissue mobilization (IASTM) market, which Mastercraft Ventures estimates includes approximately 135,000 U.S. practitioners. Its technology offers practices the potential to improve both patient care and business performance.

“We believe the next generation of healthcare technology will be driven by practitioner-led insights that connect software and AI directly to the physical tools they use every day,” said Mason Cook, Managing Director of Mastercraft Ventures. “MyoWorks has the potential to

improve practice efficiency while creating an entirely new source of clinical data that enables AI to impact patient outcomes and practitioner efficiencies.”

The investment reflects Mastercraft Ventures’ commitment to backing innovative Wisconsin startups that develop new technologies and create opportunities for economic growth across the state.

“We invest in founders who turn earned insight into innovative, scalable businesses,” Cook added. “Dr. Quick has identified an opportunity to bring intelligence to traditional treatment tools, improving patient care and creating new value for practitioners.”

For more information, visit www.myoworks.us

About Mastercraft Ventures

Mastercraft Ventures is a venture capital fund focused on investing in Wisconsin’s earliest venture-scale founders. Mastercraft Ventures leads equity investment rounds across a broad range of industries, technologies, and products. www.mastercraftvc.com

About MyoWorks

MyoWorks builds smart therapy tools with integrated software for chiropractors, physical therapists, and other musculoskeletal care providers. Its connected tools capture treatment data and generate clinical documentation, helping practitioners improve efficiency, track patient progress, and make more informed clinical decisions. www.myoworks.us

SOURCE MyoWorks

Financing co-led by Norwest and SV Health Investors’ MedTech Convergence Fund will fund launch of Nanopath’s FDA 510(k) study for its point-of-care vaginitis test in support of potential expansion of its pipeline into UTIs and STIs, and build-out of its team ahead of proposed commercialization

CAMBRIDGE, Mass., Nov. 10, 2026 — Nanopath, a point-of-care diagnostics company enabling laboratory-quality molecular testing in minutes, today announced the close of a $25 million Series B financing round, which includes $2 million in non-dilutive grant financing. The round is co-led by Norwest and SV Health Investors’ MedTech Convergence Fund, alongside strategic participation from the Labcorp Venture Fund. New and existing investors also participated, including Elderberry Ventures, GingerBread Capital, and Alumni Ventures.

As part of the financing, Catherine Kiani, J.D., Managing Partner at Elderberry Ventures, and Mindy Nye, Ph.D., Vice President, Labcorp Diagnostics, have joined the Nanopath Board as Observers.

“Nanopath is developing truly transformative technology with the potential to reshape the molecular diagnostics industry and dramatically improve patient outcomes,” said Jeff Crowe, Senior Managing Partner at Norwest. “We are beyond excited to continue supporting the company at this key inflection point.”

Nanopath has developed the first clinical diagnostics platform built on plasmonic biosensing. The company’s proprietary optical biosensing technology is designed to enable molecular detection without nucleic acid amplification, a step required by PCR-based tests. “We’ve spent years developing and pressure-testing a fundamentally new approach to molecular diagnostics for patients who have been overlooked for far too long,” said Alison Burklund, Ph.D., Co-Founder & Co-CEO of Nanopath. “This funding brings us closer to the next and most important step – translating that innovation into meaningful clinical impact.”

The funding will support key milestones toward the potential commercial launch of Nanopath’s 15-minute point-of-care vaginitis assay, including manufacturing scale-up and initiation of Nanopath’s Food and Drug Administration 510(k) clinical study. Nanopath will also use the funding to expand its team across clinical and commercial functions as it prepares for launch. “We’re incredibly proud of the extraordinary team we’ve built at Nanopath and our shared commitment to transforming women’s healthcare,” said Amogha Tadimety, Ph.D., Co-Founder & Co-CEO of Nanopath. “We’re grateful for the confidence of our investors and excited to build on this momentum as we enter our next phase of growth.”

By delivering accurate results during a single visit, Nanopath aims to establish a new standard of care for women’s health and expand access to high-quality diagnostics for women across the United States. Over time, the platform is expected to expand to other clinical indications, improving healthcare by making sophisticated diagnostics more accessible at the point of care.

The vaginitis test is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration. Commercial availability is subject to successful completion of development activities and applicable regulatory review.

About Nanopath
Nanopath is a women-led company dedicated to improving health equity worldwide, starting with women’s health. Nanopath’s proprietary molecular diagnostic testing platform takes a radically new approach to how clinicians characterize human health. The company’s novel biosensing technology has the potential to enable fast, high-complexity testing at the point-of-care, rather than in centralized laboratories. The company is headquartered in Cambridge, Mass., at The Engine built by MIT, a premier facility for high-potential, tough-tech start-ups. Founded in 2020, Nanopath has raised more than $46 million, and is backed by Norwest, the Medtech Convergence Fund, an SV Health Investors Fund, Elderberry Ventures, GingerBread Capital, Alumni Ventures and the Labcorp Venture Fund. For more information, visit www.nanopath.com.

SOURCE Nanopath

Backed by Blumberg Capital, the company formerly known as QuilrAI has grown revenue 5x in six months and now has 2.25 million agents under management for customers including Sentara Health, Alter Domus, and Concentrix

SAN FRANCISCO, Nov. 10, 2026 — AI agents are already operating across the enterprise, multiplying autonomously and acting at a speed traditional security was never built to govern. WhiteMatter, which quietly built its platform under the name QuilrAI, has raised $20M in Series A funding to secure and operationalize every agent, model, and AI interaction across the enterprise from pre-production governance and validation to securing every action at runtime. 

Blumberg Capital led the round, with participation from existing investors Crew Capital and Sprout & Oak.

The problem is architectural: enterprise security was designed for humans and deterministic software that behaves predictably. AI introduces a different kind of actor – autonomous agents that can access sensitive information, create artifacts, make decisions, move across systems, and behave unpredictably, like spawning and influencing new agents. Securing that environment requires controls purpose-built for agents, but not just at runtime, rather where AI workflows are being built, deployed, and operating. Yet most of today’s solutions still monitor from the outside in, detecting and escalating risky behavior after it happens rather than controlling it at the source before deployment. 

“Despite all the discussion about pausing AI development, enterprises are doing the opposite,” said Vidit Arora, Founder and CEO of WhiteMatter. “AI technology is too powerful, the opportunity is too significant, and the competitive pressure is too real to put it back in the box. Companies that slow down AI adoption risk being overtaken by competitors that move fast, stay secure, and scale AI with confidence, which is exactly why we built WhiteMatter.”

Rather than slowing AI adoption, WhiteMatter is the platform enterprises run their AI agents through, present everywhere AI is used, built, and run: endpoint and browser, SaaS, cloud, and code. It governs and deploys every agent, model, and MCP server in the environment; secures and observes each action before and after it executes; and optimizes agent traffic as well as spend through one controlled gateway. Point solutions cover one layer. WhiteMatter covers the system.

For every agent an enterprise deploys, WhiteMatter can deploy a dedicated Guardian agent to enforce policy on every action it takes. If agents multiply autonomously, WhiteMatter scales with them, automatically provisioning a new Guardian for every new agent to ensure continuous, policy-driven control across the enterprise.

WhiteMatter is already deployed at companies including Sentara Health, Alter Domus, New American Funding, Concentrix, and many Fortune 500 organizations. In 2026, demand accelerated sharply: the company tripled its customer base, grew revenue fivefold over the past six months, and achieved approximately 200% net revenue retention with zero customer churn.

“At Sentara Health, our mission is to improve health every day, and technology is increasingly important to how we deliver on that mission. As an integrated health system with both care delivery and health plan services, we made the decision early to operationalize AI rather than simply pilot it. Today, across our 35,000-person workforce, AI is increasingly becoming part of how we work, deliver care and serve our patients, members, and communities,” said Zishan Siddiqui, Chief Information Security Officer at Sentara Health. “WhiteMatter is helping us scale that adoption responsibly by providing greater visibility into how AI is being used, protecting sensitive information at the point of use, and guiding our workforce toward appropriate behaviors and tools in real time. We’re not governing AI to slow innovation. We’re creating the trust and guardrails that allow us to innovate responsibly, keep saying yes, and ultimately advance our mission of improving health every day.”

“At Alter Domus, we scale practical AI with measured returns: squads of Industrialized Agents in production, and work that used to take a quarter now takes a week,” said Demetry Zilberg, CTO of Alter Domus. “That pace is only responsible if governance keeps up. With WhiteMatter in our cyber defense stack, every agent is governed before it goes live, every tool call is policy-checked at one gateway, and the telemetry shows us where AI actually creates value. Security, adoption, and enterprise value aren’t separate conversations here. They’re one lifecycle, and we can see all of it.” 

Today, WhiteMatter has more than 2.25 million agents under management across customer environments, with over 5.5 million projected by year end. The company has governed 116 billion AI interactions and saved its customers over 11 trillion tokens in the past nine months alone.

QuilrAI, now WhiteMatter, grew out of Arora’s experience building enterprise security. As a founding member of Securonix, he spent more than a decade helping build security products at scale. As AI shifted from a tool people use to agents capable of making autonomous decisions, Arora saw the traditional security model begin to break. He founded QuilrAI on the belief that companies would need to rethink enterprise control and infrastructure for a world built around agents, a thesis that has since grown into WhiteMatter’s broader vision to help secure and operationalize the agentic enterprise.

“Every wave of enterprise computing eventually produced its own security layer, from the network to the cloud to identity,” said Pramod Gosavi at Blumberg Capital. “Agents are the next wave and could soon outnumber employees inside enterprises, requiring a governance layer built natively for them. We backed WhiteMatter because its platform approach and Guardian agent model give enterprises the guardrails an autonomous workforce needs, at a scale no human security team could manage manually.”

The funding will support research, development, and go-to-market expansion, alongside a significant investment in its executive leadership team. Together, the investments will help  WhiteMatter build toward its vision of becoming the security and operational layer for AI wherever it is deployed, making every agent matter.

To learn more about WhiteMatter, visit https://whitematter.io/.

About WhiteMatter

WhiteMatter, formerly QuilrAI, is the first agent-native company built to secure and operationalize the agentic enterprise across the entire AI agent lifecycle. Foundation models are non-deterministic, so protecting agents only at runtime leaves every decision to the last millisecond and every alert to the security team. WhiteMatter treats AI security as a deployment problem first: every agent is assessed, governed against policy, and deployed from an approved blueprint before reaching production; while every action is governed before execution and every outcome is measured and validated.

Powered by its Guardian agent architecture, WhiteMatter brings continuous governance and control to the agents, models, tools, and integrations powering the enterprise. More than 2.25 million WhiteMatter Guardian agents run in customer environments today, governing more than 116 billion AI interactions. Its decision architecture delivers policy decisions in 2.24 milliseconds, processes up to 7,800 actions per minute, and has demonstrated zero double executions in one million tests.

WhiteMatter serves enterprises including Sentara Health, Alter Domus, New American Funding, Concentrix, and many other Fortune 500 organizations. It is currently backed by Blumberg Capital, Crew Capital, and Sprout & Oak. Headquartered in San Francisco and Austin, WhiteMatter enables enterprises to accelerate AI adoption without compromising security or control.

Govern. Secure. Optimize. Make Every Agent matter.

SOURCE WhiteMatter

Led by Insight Partners, the new funding will support the launch of Charta for Providers and Charta for Payers, bringing one AI standard to both sides of the claim.

• The $55 million funding round brings Charta Health’s total funding to $85 million and is Charta’s third round in less than two years.
• Charta Health grew revenue 10x in the last 12 months with both health plans and provider organizations.
• Charta already touts leading enterprise healthcare clients including American Family Care, Grow Therapy, and Pediatric Associates Family of Companies.

SAN FRANCISCO, Nov. 10, 2026 — Charta Health, the AI medical chart review platform built for billing accuracy, today announced a $55 million Series B round led by Insight Partners. Existing investors Madrona, Bain Capital Ventures, and South Park Commons also participated, alongside QuantumLight.

The funding will accelerate Charta’s AI research and development and officially launch Charta for Providers and Charta for Payers. The two businesses run on one AI engine and serve both providers and health plans, making Charta one of a few AI companies with dedicated offerings for each vertical.

A single source of truth for healthcare payment

The round comes as AI reshapes how healthcare gets paid. A 2025 study estimated that in 2023, claims adjudication cost hospitals and health systems more than $25 billion. Nearly $18 billion of that total was potentially wasted on a cycle of denials and appeals that drains the U.S. healthcare system. That cycle has worsened as insurers and healthcare providers each adopt AI tools that generate more denials and appeals, the costs of which are ultimately passed on to taxpayers and consumers.

Charta proposes a different approach: one standard of accuracy, applied before the claim is submitted. Today, insurers and providers often review the same records using different tools and different standards, which leads to disagreement over coding, denials, and appeals. Charta brings the same AI to both sides, so health plans and providers work from shared standards of accuracy before a claim is ever submitted.

“We came to healthcare as engineers and saw a system where the most important data was locked in documents no one had time to read,” said Justin Liu, CEO and co-founder of Charta Health. “Charta unlocks that data. When every chart gets reviewed, accuracy stops being a guess. Payers and providers should agree on the chart before a claim goes out, not fight about it after. That’s how we end the costly cycle of denials and appeals, and put billions of dollars back into patient care.”

Built for both sides of the claim

Charta’s AI reads clinical documentation the way an expert coder and auditor would, flagging missing codes the chart supports and removing those the documentation doesn’t adequately support. Charta has grown its revenue 10x in the last 12 months and raised three rounds in under two years as investor demand kept pace with growth.

“Healthcare payments depend on the medical chart, and charting errors cause costly problems across the entire process,” said Jeff Horing, Co-founder and Managing Director at Insight Partners. “As payers and providers both adopt AI, we believe the opportunity lies in getting the underlying record, or the ‘ground truth,’ right before a claim is submitted. Charta pairs AI with customer-specific coding expertise and serves both sides of that market. We are excited to partner with Justin, Scott, and the team as they scale.”

Charta’s founders, CEO Justin Liu and CTO Scott Morris, came from Rockset, the real-time AI data company that became OpenAI’s first product acquisition. Before building Charta, Liu and Morris spent a year earning Certified Professional Coder credentials and interviewing more than 100 healthcare leaders. Today, Charta requires its engineering and growth teams to get certified in medical coding as well.

Charta for Payers

Today’s Series B announcement coincides with the launch of Charta for Payers, a suite of products that expands Charta’s AI offerings for health plans. Designed in partnership with one of the nation’s largest health insurers, Charta for Payers includes six AI-powered products that enable health plans to achieve greater accuracy and operational efficiencies:

• Retrospective HCC coding
• AI-automated second-pass coding
• Smart coding platform
• Prospective risk adjustment intelligence
• HCC validation and audit workflow
• HEDIS and quality care gap detection

Charta for Payers helps insurers participating in government-paid programs achieve greater accuracy and efficiencies across diagnosis coding and quality improvement. Both are urgent industry priorities as regulators pursue an agenda of reducing waste, fraud, and abuse in the healthcare system.

Charta for Providers

Series B financing enables Charta to expand its successful provider offering to new specialties.

Charta for Providers reviews every chart before claim submission, checking it against coding guidelines, payer rules, and each organization’s own clinical protocols. Findings surface for human approval inside the electronic health record. With Charta, providers submit claims built to hold up, resulting in fewer denials and reduced clawback risk. Customers include some of the largest healthcare enterprises in the U.S., such as American Family Care, Grow Therapy, and Pediatric Associates Family of Companies.

“As Grow scales access to mental health care, accurate documentation is essential to doing right by our patients, our providers, and our payer partners,” said Brynna Pietz, Vice President of Clinical and Insurance Operations at Grow Therapy. “Charta helps us review charts at a scale that wouldn’t be possible manually, so our clinicians can stay focused on care.”

About Charta Health

Charta Health delivers autonomous AI chart review to healthcare providers and insurance companies. By using AI to ensure that claims are accurately coded and adequately supported by clinical documentation, Charta helps providers get paid correctly for the care they provide. For health plans, Charta analyzes clinical documentation at scale to support revenue integrity and compliance for Medicare Advantage and ACA Marketplace plans. Charta is backed by Insight Partners, Bain Capital Ventures, Madrona Venture Group, and other leading investors. Learn more at chartahealth.com.

About Insight Partners

Insight Partners is a global AI and software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2026, the firm has over $90 billion in regulatory assets under management. Insight Partners has invested in more than 900 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has a global presence with leadership in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.

SOURCE Charta Health

ARLINGTON, Va., Nov. 10, 2026 — U.S. Dock & Door (“USDD”), a service platform focused on the maintenance, repair and installation of commercial loading dock equipment, entry systems, and residential garage doors, is pleased to announce its investment in High Touch Overhead Door (“High Touch”).

Headquartered in White Plains, New York, High Touch is a leading provider of commercial overhead door and loading dock repair, maintenance, retrofit and installation services across the Tri-State area. The company is led by Matthew Nishri, who will continue to lead High Touch following USDD’s investment. High Touch’s highly recurring, service-oriented business mix aligns with and strengthens USDD’s existing operations, further expands USDD’s Northeast footprint, and provides an attractive beachhead for continued growth across neighboring markets.

“The investment in High Touch represents an important step in U.S. Dock & Door’s strategy to build a national leader in dock and door service and installation solutions. High Touch brings a strong reputation in the Tri-State market and highly complementary commercial service and retrofit capabilities that further strengthen our platform across service capabilities and geographies,” said Brian Pfeifer, Chief Executive Officer of USDD. “Matthew has built an exceptional business with a strong foundation for continued growth, and we are excited to partner with him for the company’s next chapter.”

“We are thrilled to be partnering with Brian and the USDD team. We believe that this partnership will allow us to invest in continued growth within our market, while expanding into new geographies,” said Matthew Nishri, President of High Touch.

USDD is a platform investment of Soundcore Capital Partners (“Soundcore”). Soundcore remains focused on partnering with strong operators and market-leading businesses in targeted geographies who will benefit from the scale of USDD. “Our partnership with High Touch is a strategic investment in the company’s people, reputation, and high quality of service. We look forward to supporting the company’s sustained growth within the USDD platform,” said Jonathan Tanenbaum, a Partner at Soundcore.

Terms of the transaction were not disclosed.

About US Dock & Door
US Dock & Door is a service-based platform of operating companies that maintain, repair and install commercial loading dock equipment, entry systems, and residential garage doors. With over 50 years of history, USDD’s operating companies primarily service the Southeast and Northeast markets and work with customers across a variety of industries including manufacturing, distribution, life sciences, retail, education, residential homeowners and home builders. For more information, please visit www.usdockdoor.com

About High Touch
High Touch is a leading provider of commercial overhead door and loading dock repair, maintenance, retrofit and installation services across the Tri-State area, with a focus on New York and Connecticut. Headquartered in White Plains, New York, the Company serves a diverse base of primarily commercial customers through a highly service-oriented model focused on responsive, high-quality solutions. Founded in 2003, High Touch has built a strong reputation in its local markets through its expertise in overhead doors and loading dock systems and its focus on recurring repair, maintenance and retrofit needs. For more information, please visit www.ht-garagedoors.com

About Soundcore
Soundcore Capital Partners was founded in 2015 by Jarrett Turner and is based in New York. Soundcore is a thesis-driven private equity firm that specializes in buy-and-build investments in the lower middle-market that are headquartered in the United States and Canada. Soundcore has completed 115 acquisitions across 14 platforms and focuses primarily on business & outsourced services, industrial services, specialty manufacturing, and value-added distribution sectors. For more information, please visit www.soundcorecap.com

MEDIA CONTACT:
Elizabeth Olt
[email protected]
(212) 812-1432

SOURCE US Dock & Door